Consequently, five genes (CHMP2A, EGFR, MDH1, PKN2, and HSP90B1) with robust evidence of AD-specific dysregulation were prioritized for subsequent regulatory network construction and in vivo validation in APP/PS1 mice. This evidence concerns the gene CHMP2A and Alzheimer disease.